newsfilter
← Latest News
PR Newswire·

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

-GeneRide® LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers -Proprietary AAV transfection process, harnessing mAAVRx™ system, showed 15- to 30-fold yield increase over standard processes -